This entry covers evaluation under DC 7904. A clinician establishes the diagnosis separately.
How is it connected to service?
The applicable direct, secondary, aggravation or presumptive route determines the service-connection evidence. Use the evidence guide to distinguish these routes.
Explore service-connection evidence →What do the rating levels describe?
A diagnosis does not automatically establish a percentage. These are the source requirements for evaluating severity; related notes and exceptions still apply.
Compare these levels with the original rating table
Find DC 7904 in the rating schedule
The highlighted row marks this code. Nearby rows provide context and can describe other conditions. Use the full schedule for applicable headings, footnotes and exceptions.
| Rating | |
|---|---|
| Note (2): This evaluation shall continue for six months after initial diagnosis. Thereafter, rate residuals of disease or medical treatment under the most appropriate diagnostic code(s) under the appropriate body system (e.g., eye, digestive, mental disorders). | |
| Note (3): If eye involvement, such as exophthalmos, corneal ulcer, blurred vision, or diplopia, is also present due to thyroid disease, also separately evaluate under the appropriate diagnostic code(s) in § 4.79, Schedule of Ratings—Eye (such as diplopia (DC 6090) or impairment of central visual acuity (DCs 6061-6066)). | |
| 7904 Hyperparathyroidism: | |
| For six months from date of discharge following surgery | 100 |
| Note (1): After six months, rate on residuals under the appropriate diagnostic code(s) within the appropriate body system(s) based on a VA examination. | |
| Hypercalcemia (indicated by at least one of the following: Total Ca greater than 12 mg/dL (3-3.5 mmol/L), Ionized Ca greater than 5.6 mg/dL (2-2.5 mmol/L), creatinine clearance less than 60 mL/min, bone mineral density T-score less than 2.5 SD (below mean) at any site or previous fragility fracture) | 60 |
| Note (2): Where surgical intervention is indicated, this evaluation shall continue until the day of surgery, at which time the provisions pertaining to a 100-percent evaluation shall apply. | |
| Note (3): Where surgical intervention is not indicated, this evaluation shall continue for six months after pharmacologic treatment begins. After six months, rate on residuals under the appropriate diagnostic code(s) within the appropriate body system(s) based on a VA examination. | |
| Symptoms such as fatigue, anorexia, nausea, or constipation that occur despite surgery; or in individuals who are not candidates for surgery but require continuous medication for control | 10 |
Related notes and evaluation rules
Note (1): After six months, rate on residuals under the appropriate diagnostic code(s) within the appropriate body system(s) based on a VA examination.
Note (2): Where surgical intervention is indicated, this evaluation shall continue until the day of surgery, at which time the provisions pertaining to a 100-percent evaluation shall apply.
Note (3): Where surgical intervention is not indicated, this evaluation shall continue for six months after pharmacologic treatment begins. After six months, rate on residuals under the appropriate diagnostic code(s) within the appropriate body system(s) based on a VA examination.
Note (4): Following surgery or other treatment, evaluate chronic residuals, such as nephrolithiasis (kidney stones), decreased renal function, fractures, vision problems, and cardiovascular complications, under the appropriate diagnostic codes.
Note (1): After six months, rate on residuals under the appropriate diagnostic code(s) within the appropriate body system(s) based on a VA examination. |
Note (3): Where surgical intervention is not indicated, this evaluation shall continue for six months after pharmacologic treatment begins. After six months, rate on residuals under the appropriate diagnostic code(s) within the appropriate body system(s) based on a VA examination. |
Note (4): Following surgery or other treatment, evaluate chronic residuals, such as nephrolithiasis (kidney stones), decreased renal function, fractures, vision problems, and cardiovascular complications, under the appropriate diagnostic codes. |
Which evidence addresses the questions?
- Diagnosis and history: Records identifying the current diagnosis, onset, course, and relevant medical history.
- Diagnostic tests and measurements: Condition-relevant tests, imaging, laboratory results, and objective measurements.
- Symptoms and episodes: Records or statements documenting symptoms, severity, frequency, duration, and episodes.
- Treatment and medications: Treatment records, medication history, procedures, and therapy documentation.
- Clinical findings: Examination findings that are relevant to the public DBQ or rating criteria.
- Scars and residual findings: Records describing relevant scars and residual physical findings.
- Functional impact: Medical and lay evidence describing work and daily-activity effects.
- Service connection evidence: Evidence addressing an in-service event, exposure, disease, injury, continuity, or a secondary relationship.
Find evidence in the Thyroid and Parathyroid questionnaire
Use these section names and page numbers to locate the examiner’s findings. Some sections apply only to particular diagnoses within this family.
- diagnosis · p. 1, 2
- medical history · p. 2, 3
- thyroid: findings, signs, and symptoms · p. 3, 4
- parathyroid: findings, signs, and symptoms · p. 4, 5
- physical exam · p. 5, 6
- reflex exam · p. 6, 7
- tumors and neoplasms · p. 7, 8
- other pertinent physical findings, complications, conditions, signs, symptoms, and scars · p. 8
- diagnostic testing · p. 8, 9
- functional impact · p. 10
- remarks · p. 10
Shared library and examination references
How an independent medical review works →Sources and scope
Clinical and evidence sources
Guide source check: 2026-11-06. Rating-library snapshot: June 30, 2026. Source coverage is distinct from clinical review. This page does not diagnose, adjudicate a claim, or collect medical records.
Shared reference edition 1.2.4 · source check 2026-11-06. Coverage is stated for each framework and is distinct from clinical review. Rating-source snapshot: 2026-06-30.